BofA Lifts Price Target to $265, Wells Fargo to $240 as 2026 Normalization Comes Into Focus
Danaher Corporation (NYSE: DHR) is back in the spotlight on Monday, December 15, 2025, after two fresh Wall Street updates pushed Danaher stock back into the “what’s next” conversation for life-science and diagnostics investors. In afternoon trading, DHR hovered around $227 per share, modestly higher on the day.
The bigger story isn’t a dramatic price move—it’s the shift in tone among analysts: multiple firms are positioning 2026 as a potential “normalization year” for demand trends across life sciences tools and diagnostics, with Danaher seen as one of the large-cap bellwethers.
Below is a full, publication-ready breakdown of today’s news, forecasts, and analyses shaping Danaher stock—plus the near-term catalysts and…
